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S U M M A R Y
Objectives: While the prevalence of Group B streptococcus (GBS) colonization is important, little is
known about invasive GBS (iGBS) disease in tropical areas. Our objective was to assess the burden of iGBS
disease among non-pregnant adults.
Methods: A prospective hospital-based study of all non-pregnant adult patients with iGBS disease was
conducted between January and December 2011 in Saint Pierre, Re´union Island, to assess its cumulative
incidence rate (CIR). Capsular serotyping and multilocus sequence typing were performed to
characterize GBS isolates. Case-control study was done to identify risk factors.
Results: The overall CIR of iGBS disease was 10.1 per 100,000. The CIR in elderly patients ( 65 yrs) was
estimated at 40.6 per 100.000, and that of adults (15-64 years) at 6.7 per 100.000. Aboriginal origin in the
Indian Ocean and overweight were both associated with iGBS disease. The most prominent clinical forms
were osteo-articular and skin/soft tissue infections, as a consequence of diabetic foot. The serotypes were
classic, type-Ia being the most prevalent. The hyper virulent ST-17 (CC17) was associated with type-III.
Conclusions: The incidence of iGBS disease found in Re´union island is twofold that usually reported. This
burden is linked to overweight in aboriginal people from the Indian Ocean.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus agalactiae (Group B streptococcus [GBS]), a
pathogen well known to cause signiﬁcant morbidity and mortality
in the neonate and in pregnant women, has become a global
concern worldwide among non-pregnant adults, especially in the* Corresponding author. Department of Infectious disease, CHU La Re´union,
Saint-Pierre, BP 350, 97448 Saint-Pierre Cedex, Re´union Island, France.
Tel.: +00 (33) 262 35 91 65
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).elderly with underlying conditions.1 Populations usually consid-
ered ‘‘at-risk’’ encompass patients with type-2 diabetes mellitus
(T2D), neurologic disease, renal failure, malignancies, cirrhosis,
HIV infection or those undergoing intravenous catheterization. In
these populations, GBS causes a broad-spectrum disease charac-
terized by various invasive infections including bacteraemia
without focus, skin/soft-tissue and osteo-articular infections,
pneumonia, urosepsis, endocarditis, peritonitis, meningitis and
empyema, streptococcal toxic shock syndrome (STSS).1
In the literature, the cumulative incidence rates (CIR) of invasive
GBS (iGBS) disease usually range between 2.4 and 9.2 cases per
100,000 non-pregnant adults,2,3 and most publications come fromciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ment located in the Indian Ocean, severely affected by the pandemic
of obesity and T2D,4 we had previously shown higher incidence
rates of early-onset GBS neonatal infections than in metropolitan
France.5We also documented the prevalence of GBS colonization in
pregnant woman and conﬁrmed the role of obesity previously
found in the United States, and of ethnicity, evidenced in the USA
and the Netherlands, as predictors for GBS carriage during
childbearing age.6–8 In this context, we wished to know whether
the high incidence rates found in younger age categories could also
encompass non-pregnant adults, and to what extent the host or
pathogen factors contribute to the disease burden.
The objectives of this prospective hospital-based cohort study
were to characterize the clinical and microbiological features
associated with iGBS disease among non-pregnant adults and to
assess its disease burden and risk factors in a tropical setting.
2. Methods
After oral consent, in accordance with the recommendations of
the local Committee for Clinical Research, we collected data for all
consecutive patients over age 18 years admitted consecutively to
the Department of Infectious Diseases of the teaching hospital of
Saint Pierre, Re´union Island, between 1 January and 31 December,
2011. The subjects with an invasive GBS infection and for whom
GBS was isolated from a sterile specimen (blood or urine culture,
synovial or peritoneal ﬂuid culture and bone biopsy) were enrolled
as invasive GBS disease cases. Clinical data were extracted from
chart reviews, and specimens underwent serotyping and genotyp-
ing, the latter based on a two-multiplex RT-PCR assay.9
Age-appropriate incidence rates were compared to US stan-
dards.1 Case-control study was performed to assess the role of age,
gender, place of birth, obesity and T2D in iGBS disease, taking
uninfected non-pregnant adults (GBS carriers or not), or uninfected
GBS-carrier pregnant women as controls using our Medical
Statistics Database. We used Poisson regression models for binary
data with a robust variance option10 to provide incidence rate ratioFigure 1. Age-speciﬁc incidence rates of invasive GBS diseases among non-pregnant ad
Note. US data for non-pregnant adults are extrapolated from pregnant and non-pregnant
program network of the Centers for Disease Control and Prevention.1 In the USA, th
approximately 1:2.3.estimates. Stata (version 13.01, StataCorp. 2013, Texas, USA) was
used for ﬁtting the models. Statistical signiﬁcance was set at
P = 0.05.
3. Results
Over the one-year study period, 22 non-pregnant adult cases
were diagnosed with an invasive GBS infection out of an adult non-
pregnant population of roughly 217,000 persons, which led to an
overall CIR of iGBS disease of 10.1 per 100.000 (95% conﬁdence
interval: 6.3-13.9 per 100.000). The median age of the patients was
59 years (range: 25-93 years). The CIR in elderly patients ( 65 yrs)
was thus estimated to be 40.6 per 100.000 (Figure 1). The clinical
features at presentation to hospital, the antibiotic treatment and
its duration, and the outcomes of the 22 patients are depicted in
Table 1.
Osteo-articular infections (12/22) topped the list, as the
outcome of primary diabetic foot (9/12), orthopedic prosthesis
(2/12) or chronic prostatitis (1/12: for this patient (n85), urine
culture and vertebral biopsy was positive for Streptococcus
agalactiae). Skin/soft tissue infections were observed in three
patients (3/22: cellulitis, 2/3; necrotizing fasciitis, 1/3), two of
them being diabetic. Three patients exhibited urosepsis (3/22),
these consisting of one acute pyelonephritis (1/3), one acute
orchitis (1/3), or the outcome of pelviureteric junction syndrome
(1/3). Patient n83 suffered from peritonitis (1/22) following an
episode of acute renal failure, as the result of infection of his
peritoneal dialysis catheter. In three patients (3/22), a bacteriemia
without focus was diagnosed.
Amoxicillin alone (8/22) or in combination with clavulanate (3/
22) was used in half of the patients. It was defeated in a diabetic
foot followed by amputation. Other treatments were probabilistic
and guided by the clinical presentation and underlying conditions.
The outcome was favourable for 72.7% of iGBS disease (16/22),
after removal of the orthopedic implant in one case. In seven
patients, the issue was pejorative marked by a relapse in two cases,ults in Reunion island and the USA.
 adults enrolled in the ABCs Active Bacterial Core Surveillance of Emerging Infections
e pregnant to non-pregnant ratio in the adult population with GBS invasive is
Table 1
Clinical features, treatment and outcome of the 22 patients.
Patient Age Clinical presentation Treatment Outcome
1 53 Diabetic foot infection with cellulitis* Clindamycin (4 weeks) Favourable
2 47 Diabetic foot infection with osteomyelitis* Piperacillin/tazobactam (6 weeks) Amputation
3 38 Peritonitis (peritoneal dialysis) Amoxicillin (4 weeks) Favourable
4 58 Acute epididymo-orchitis Amoxicillin (4 weeks) Favourable
5 27 Vertebral osteomyelitis with chronic prostatitis Amoxicillin (6 weeks) Favourable
6 60 Diabetic foot infection with osteomyelitis* Amoxicillin/clavulanate (6 weeks) Favourable
7 72 Diabetic foot infection with osteomyelitis* Amoxicillin (6 weeks) Favourable
8 70 Diabetic foot infection with osteomyelitis* Amoxicillin (6 weeks) Amputation
9 91 Acute pyelonephritis Ceﬁxime (10 days) Relapse
10 33 Bacteriemia without focus Amoxicillin (2 weeks) Favourable
11 91 Bacteriemia without focus Amoxicillin/clavulanate (10 days) Favourable
12 46 Obstructive pyelonephritis Ceftriaxone (3 weeks) Favourable
13 65 Diabetic foot infection with osteomyelitis* Amoxicillin/clavulanate (4 weeks) Favourable
14 60 Diabetic foot infection with osteomyelitis* Clindamycin (5 weeks) Favourable
15 49 Necrotizing fasciitis Piperacillin/tazobactam (4 weeks) Amputation
16 25 Orthopedic prosthesis infection Oxacillin Favourable
after removal
of implant
17 67 Diabetic foot infection with osteomyelitis* Amoxicillin (6 weeks) Favourable
18 84 Diabetic foot infection with cellulitis* Ceftriaxone (1 week) Death
19 93 Diabetic foot infection with osteomyelitis* Ciproﬂoxacin + Rifampicin (6 weeks) Favourable
20 62 Diabetic foot infection with osteomyelitis* Amoxicillin (6 weeks) Favourable
21 53 Bacteriemia without focus Oxacillin (10 days) Favourable
22 71 Orthopedic prosthesis infection Oxacillin + Rifampicin (6 weeks) Relapse
* Diagnosis was made using hemoculture and/or bone biopsy.
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case.
Underlying conditions were found in 63.6% (14/22), of which
T2D ranked ﬁrst, observed in half of the cases (11/22), ahead of
cancer (2/22) and neurogenic bladder (1/22).
Serotyping was performed for 17 of 22 specimens. The most
frequent capsular serotypes identiﬁed were, in decreasing order: Ia
(41.2%), II (29.4%), III (17.6%), V (11.8%). Two strains of the
17 studied were resistant to erythromycin due to the presence of
the ermB gene (type-V strain), or due to the mef gene (type-Ia
strain). The hypervirulent ST17 (CC17) factor was found in two
type-III isolates. All isolates were sensitive to G penicillin.
The relationships between age, gender, place of birth, obesity or
T2D and three different contexts of GBS infections are displayed in
Table 2.
4. Discussion
Our study reveals one of the highest incidence rates of iGBS
disease ever reported in non-pregnant adults (10.1 per
100,000), for which it almost reaches levels usually observed
in ‘‘high-risk’’ populations such as black adults (Figure 1).1–3,6–8
This high incidence can be explained by the combination of
several risk factors highly prevalent on Re´union Island, such as
obesity,4 T2D,4 black (African) descent6 or hyper precocious
sexuality.12,13 In our study, T2D is thus associated with half the
cases (11/22), which exceeds the range of 20% to 48% previously
reported worlwide.1–3,11,14,15 This ﬁnding was expected given
the prevalence of T2D in our community (20% of the adults age
30 to 69 years), especially in the elderly (men: 34%, women:
40% of the 60-69 years category).4 Importantly, invasive GBS
disease in non-pregnant adults was associated with overweight
and place of birth (Table 2), highlighting Indian Ocean
indigenous populations as vulnerable to the most severe forms
of GBS infection.
As a consequence, in Re´union Island, the clinical spectrum of
iGBS disease is shifted toward the complications of the diabetic
foot (e.g., osteo-articular and skin/soft tissue infections, Table 1).3This distribution contrasts those observed in the USA or in France,
where bacteraemia without focus and pneumonia predominate.1–
3,11,14,15 We explain it by both the high prevalence of T2D and the
community origin of 100% of the infections observed in La Re´union,
unlike the hospital-acquired origin found in most US or French
patients. Indeed, even though living in long-term care facilities
(LTCF) is a well-known risk factor for invasive GBS disease,15 in La
Re´union 92% of the elderly dependent persons are community
residents, while overall, a contrario 80% of these usually live in LTCF
in Europe. For these reasons, we believe that the iGBS disease
spectrum in Re´union island is more representative of the clinical
forms usually encountered in the Indian Ocean than those found in
Europe or in the USA.16
The distributions of the serotypes and of the resistance genes
were classic: type Ia ranked ﬁrst, as observed for metropolitan
France, Portugal, China, Australia, New Zealand and the
USA.11,14,17,18 Erythromycin resistance was linked to the mef gene
in type-Ia and to ermB gene in type-V, the latter also conferring
resistance to clindamycin.17,19 ST17 (CC17) was found exclusively
in type-III, as found in east African adults.20
Our study has some limitations. It was not population-based, so
we may have underestimated the real burden of iGBS disease.
Notwithstanding, our estimates were likely conservative and we
think they may provide reliable ﬁgures for public health
stakeholders in our insular population.
In conclusion, in Re´union Island, the burden of invasive GBS
disease may be one of the highest ever reported. This burden is
linked to the aboriginal origin in the Indian Ocean and to
overweight, more than to black descent or type-2 diabetes mellitus
per se. Further studies are needed to decipher whether these
observations illustrate the social disadvantage of indigenous
populations or pathogen speciﬁc mechanisms.
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Table 2
Risk factors associated with invasive GBS disease in non-pregnant adults, La Reunion, 2011
Non-pregnant adult cases
with invasive GBS disease (a)
Uninfected non-pregnant adult controls
without GBS carriage (b)
Uninfected non-pregnant adult controls
with GBS carriage (c)
Uninfected pregnant women controls
with GBS carriage (d)
N=22 N =83 N=28 N=42
Risk factors n (%) n (%) IRR 95% CI P value a vs b n (%) IRR 95% CI P value a vs c n (%) IRR 95% CI P value a vs d
Gender
Male 11 (50) 57 (68.7) 0.5 0.2 – 1.1 0.094 2 (7.1) 2.6 1.3 – 4.9 0.004 0 (0) N.A N.A
Female 11 (50) 26 (31.3) 1 reference - 26 (92.9) 1 reference - 42 (100) reference -
Age (years)
15 to 44 4 (18.2) 14 (16.9) 1 reference - 14 (50.0) 1 reference - 42 (100) reference -
45 to 64 9 (40.9) 30 (36.1) 0.9 0.3 – 2.6 0.907 6 (21.4) 2.4 0.7 – 7.0 0.122 0 (0) N.A N.A
 65 9 (’40.9) 39 (47.0) 0.5 0.1 – 1.7 0.262 8 (28.6) 2.3 1.1 – 4.8 0.026 0 (0) N.A N.A
Place of Birth
Metropolitan
France
0 (0) 7 (8.4) 1 reference - 2 (7.1) 1 reference - 4 (9.5) 1 reference -
Reunion island 21 (95.4) 75 (90.4) 5380777 1.710e6 -
1.710e7
< 0.001 24 (85.7) 398400 7.410e5 -
7.410e7
< 0.001 34 (80.9) 1973177 5.510e5 -
7.010e6
< 0.001
Other Indian
Ocean islands
1 (4.6) 1 (1.2) 1.710e7 3.410e6 -
8.110e7
< 0.001 2 (7.1) 259004 3.710e5 -
1.810e7
< 0.001 4 (9.5) 1301512 2.210e5 -
7.510e6
< 0.001
Body mass index (kg/m2)
< 18.5 2 (9.1) 24 (28.9) 0.9 0.1 – 5.3 0.904 4 (14.3) 1.7 0.5 – 5.9 0.370 10 (23.8) 0.8 0.1 – 3.5 0.727
18.5 to 24.9 3 (28.6) 29 (34.9) 1 reference - 14 (50.0) 1 reference - 12 (28.6) 1 Reference -
25 to 29.9 12 (54.6) 15 (18.1) 4.5 1.4 – 14.7 0.012 5 (17.8) 3.5 1.4 – 8.6 0.005 11 (26.2) 1.4 0.4 – 4.2 0.507
 30 5 (22.7) 15 (18.1) 3.0 0.8 – 11.5 0.102 5 (17.8) 2.7 0.9 – 7.6 0.055 9 (21.4) 1.3 0.3 – 4.3 0.707
Comorbidity
None 8 (36.4) 35 (42.2) 1 reference - 13 (46.4) 1 reference - 34 (80.9) -
Type-2
diabetes
mellitus
11 (50.0) 33 (39.7) 0.8 0.3 – 2.0 0.657 12 (42.9) 0.6 0.2 – 1.4 0.284 8 (19.1) 2.5 1.1 – 5.6 0.019
Other 3 (13.6) 15 (18.1) 0.5 0.1 – 1.6 0.245 3 (10.7) 0.7 0.2 – 2.4 0.624 0 (0) 3.8 1.8 – 7.9 < 0.001
NOTE. Data are numbers, percentages, adjusted incidence risk ratios and 95% conﬁdence intervals estimated using three different Poisson regression models with robust variance option for a vs b, a vs c and a vs d comparisons.
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